The Hymenoptera venom study III: Safety of venom immunotherapy

One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenan...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 86; no. 5; pp. 775 - 780
Main Authors Lockey, Richard F., Turkeltaub, Paul C., Olive, Emory S., Hubbard, James M., Baird-Warren, Irene A., Bukantz, Samuel C.
Format Journal Article
LanguageEnglish
Published New York, NY Mosby, Inc 01.11.1990
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 μg and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 μg and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.
AbstractList One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 μg and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 μg and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.
One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.
One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95 days, and the largest number achieved maintenance (147 subjects, 10.4%) at day 56. Ninety-two percent of the treated subjects achieved maintenance, and 84% continued therapy, most subjects (91%) until the study was terminated. One hundred seventy-one subjects (12%) experienced 327 treatment systemic reactions (Srs). The incidence of pruritus and angioedema/urticaria was similar with mild, moderate, or severe SRs. The SR severity did not correlate with the severity of the most recent sting before entry into the Hymenoptera-venom study, the most severe historical sting SR, the most severe SR during venom skin tests, the total dose of venom, the degree of skin test reactivity, or the lowest concentration yielding a positive skin test. Most SRs occurred between 1 and 50 micrograms and at maintenance; honeybee or wasp venoms were most likely to produce SR. This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 micrograms and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.
One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). This study, the largest of its kind with the use of standardized extracts, demonstrates (1) that there was good compliance, (2) that various historical and diagnostic criteria did not predict SRs to VIT, (3) that SRs to VIT were most likely to occur between 1 and 50 mu g and at maintenance, (4) that honeybee or wasp venoms were most likely to produce an SR, and (5) that VIT is relatively safe.
Author Olive, Emory S.
Bukantz, Samuel C.
Lockey, Richard F.
Turkeltaub, Paul C.
Hubbard, James M.
Baird-Warren, Irene A.
Author_xml – sequence: 1
  givenname: Richard F.
  surname: Lockey
  fullname: Lockey, Richard F.
  organization: Tampa, Fla., USA
– sequence: 2
  givenname: Paul C.
  surname: Turkeltaub
  fullname: Turkeltaub, Paul C.
  organization: Tampa, Fla., USA
– sequence: 3
  givenname: Emory S.
  surname: Olive
  fullname: Olive, Emory S.
  organization: Tampa, Fla., USA
– sequence: 4
  givenname: James M.
  surname: Hubbard
  fullname: Hubbard, James M.
  organization: Tampa, Fla., USA
– sequence: 5
  givenname: Irene A.
  surname: Baird-Warren
  fullname: Baird-Warren, Irene A.
  organization: Tampa, Fla., USA
– sequence: 6
  givenname: Samuel C.
  surname: Bukantz
  fullname: Bukantz, Samuel C.
  organization: Tampa, Fla., USA
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19665022$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/2229842$$D View this record in MEDLINE/PubMed
BookMark eNqFkUtPwkAUhWeBQUB_Akk3Gl1U59GZzrjQGKJCQuICXE-mM7ehhrbYaUn67y3QsGV1H-fLzc05YzQoygIQmhL8RDARzyuMFQlFHKkHzB8lJpKG0QCNzutrNPb-F3czk2qIhpRSJSM6Qq_rDQTzNoei3NVQmWDfdXng68a1wWKxeAlWJoW6Dcq0l7I8b4qy3nTwrr1BV6nZerjt6wT9fH6sZ_Nw-f21mL0vQ6BC1aEDJpIkxgyk4swY65ylAIkRKlFpFNEUp4YbEhPKnFIRcVYQFuMEE-COMzZB96e7u6r8a8DXOs-8he3WFFA2XkuMperuXAQjpYjkUlwECZfx4Z0OnPZgk-Tg9K7KclO1urew0-963XhrtmllCpv5M0aUEBzTA_d24qDzaZ9Bpb3NoLDgsgpsrV2ZaYL1IU99zFMfgtOY62OeOmL_0GuTzg
CODEN JACIBY
ContentType Journal Article
Copyright 1990 Mosby-Year Book, Inc.
1991 INIST-CNRS
Copyright_xml – notice: 1990 Mosby-Year Book, Inc.
– notice: 1991 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
H94
7S9
L.6
7X8
DOI 10.1016/S0091-6749(05)80182-4
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Immunology Abstracts
AGRICOLA
AGRICOLA - Academic
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 780
ExternalDocumentID 2229842
19665022
S0091674905801824
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
354
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8F7
8FE
8FH
8P~
9JM
AAAJQ
AABNK
AACTN
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACPRK
ACRLP
ACRPL
ADBBV
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
AEBSH
AEIPS
AEKER
AENEX
AFFNX
AFJKZ
AFRAH
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIKHN
AITUG
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
C45
CAG
CJTIS
COF
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LK8
LUGTX
M27
M41
MO0
N4W
N9A
O-L
O9-
O9~
OAUVE
OBH
ODZKP
OHH
OHT
OK0
OK1
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSI
SSZ
T5K
TEORI
TWZ
UGJ
UNMZH
UV1
WH7
WOW
WUQ
X7M
XFW
YOC
YQI
YQJ
Z5R
ZGI
ZXP
ZY1
~02
~G-
~KM
AAFWJ
AAYWO
ACIEU
ACVFH
ADCNI
ADXHL
AEUPX
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKYEP
APXCP
EFKBS
IQODW
3V.
7RV
7X7
8C1
AFKRA
AFKWA
AJOXV
AMFUW
BBNVY
BENPR
BHPHI
CGR
CUY
CVF
ECM
EIF
HCIFZ
M2O
M7P
NPM
PKN
7T5
H94
7S9
L.6
7X8
ID FETCH-LOGICAL-e269t-de36bb703e8953aacddc2eeba69b9f442f0fa5a17123d9941dc61370b01e5d533
ISSN 0091-6749
IngestDate Fri Jul 11 11:01:36 EDT 2025
Fri Jul 11 08:17:43 EDT 2025
Fri Jul 11 04:32:16 EDT 2025
Wed Feb 19 02:33:51 EST 2025
Mon Jul 21 09:15:57 EDT 2025
Sun Apr 06 06:53:01 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Human
Allergy
Immunopathology
Arthropoda
Insecta
Immunotherapy
Venom
Invertebrata
Hymenoptera
Allergen
Skin test
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-e269t-de36bb703e8953aacddc2eeba69b9f442f0fa5a17123d9941dc61370b01e5d533
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 2229842
PQID 15877123
PQPubID 23462
PageCount 6
ParticipantIDs proquest_miscellaneous_80089442
proquest_miscellaneous_49918586
proquest_miscellaneous_15877123
pubmed_primary_2229842
pascalfrancis_primary_19665022
elsevier_sciencedirect_doi_10_1016_S0091_6749_05_80182_4
PublicationCentury 1900
PublicationDate 1990-Nov
PublicationDateYYYYMMDD 1990-11-01
PublicationDate_xml – month: 11
  year: 1990
  text: 1990-Nov
PublicationDecade 1990
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Journal of allergy and clinical immunology
PublicationTitleAlternate J Allergy Clin Immunol
PublicationYear 1990
Publisher Mosby, Inc
Elsevier
Publisher_xml – name: Mosby, Inc
– name: Elsevier
References Lockey, Benedict, Turkeltaub, Bukantz (bib10) 1987; 79
Package Insert-Pharmalgen: freeze-dried Hymenoptera venom/venom protein allergenic extracts. Directions for use. Pharmacia Diagnostics, Piscataway, N.J.
Golden, Valentine, Kagey-Sobotka (bib7) 1980; 92
Reisman (bib9) 1988; 671
Bousquet, Muller, Dreborg (bib3) 1987; 42
Package Insert-Albany: instructions and dosage schedule for allergenic extracts Hymenoptera venom products. Hollister-Stier Laboratories Spokane, Wash.
Van Metre, Adkinson, Amodio (bib8) 1982; 69
Golden, Valentine (bib6) 1986
Lockey, Turkeltaub, Baird-Warren (bib1) 1988; 82
Committee on Safety of Medicines Update (bib11) 1986; 293
Lockey, Turkeltaub, Olive, Baird-Warren, Olive, Bukantz (bib2) 1989; 84
References_xml – volume: 92
  start-page: 620
  year: 1980
  ident: bib7
  article-title: Regimens of Hymenoptera venom immunotherapy
  publication-title: Ann Intern Med
– volume: 671
  start-page: 383
  year: 1988
  end-page: 387
  ident: bib9
  article-title: Late onset reactions following venom immunotherapy and venom skin tests
  publication-title: Ann Allergy
– reference: Package Insert-Pharmalgen: freeze-dried Hymenoptera venom/venom protein allergenic extracts. Directions for use. Pharmacia Diagnostics, Piscataway, N.J.
– reference: Package Insert-Albany: instructions and dosage schedule for allergenic extracts Hymenoptera venom products. Hollister-Stier Laboratories Spokane, Wash.
– volume: 42
  start-page: 401
  year: 1987
  end-page: 413
  ident: bib3
  article-title: Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology
  publication-title: Allergy
– volume: 293
  start-page: 948
  year: 1986
  ident: bib11
  article-title: Desensitising vaccines
  publication-title: Br Med J
– volume: 79
  start-page: 660
  year: 1987
  end-page: 677
  ident: bib10
  article-title: Fatalities from immunotherapy (IT) and skin testing (ST)
  publication-title: J Allergy Clin Immunol
– volume: 82
  start-page: 370
  year: 1988
  end-page: 381
  ident: bib1
  article-title: The Hymenoptera venom study I, 1979–1982: demographics and history-sting data
  publication-title: J Allergy Clin Immunol
– volume: 69
  start-page: 181
  year: 1982
  ident: bib8
  article-title: A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever
  publication-title: J Allergy Clin Immunol
– volume: 84
  start-page: 967
  year: 1989
  end-page: 974
  ident: bib2
  article-title: The Hymenoptera venom study II: skin test results and safety of venom skin testing
  publication-title: J Allergy Clin Immunol
– start-page: 57
  year: 1986
  end-page: 62
  ident: bib6
  article-title: Immunotherapy with insect venoms: techniques, schedules, adverse reactions
  publication-title: Monograph on insect allergy
SSID ssj0009389
Score 1.7427915
Snippet One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). Time to maintenance averaged 95...
One thousand four hundred ten (44%) of the 3236 subjects in the Hymenoptera venom study accepted venom immunotherapy (VIT). This study, the largest of its kind...
SourceID proquest
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 775
SubjectTerms administration & dosage
Allergic diseases
Animals
Biological and medical sciences
Chi-Square Distribution
Desensitization, Immunologic
Dose-Response Relationship, Immunologic
extracts
human health and safety
Humans
Hymenoptera
Hymenoptera - immunology
immunology
Immunopathology
immunotherapy
Insect Bites and Stings
Insect Bites and Stings - therapy
Medical sciences
Skin allergic diseases. Stinging insect allergies
Skin Tests
therapy
venoms
Wasp Venoms
Wasp Venoms - administration & dosage
Wasp Venoms - immunology
Title The Hymenoptera venom study III: Safety of venom immunotherapy
URI https://dx.doi.org/10.1016/S0091-6749(05)80182-4
https://www.ncbi.nlm.nih.gov/pubmed/2229842
https://www.proquest.com/docview/15877123
https://www.proquest.com/docview/49918586
https://www.proquest.com/docview/80089442
Volume 86
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9NAEF-0ByKI-HVYP848KCgld8lmN5v4IBxyR3vXuxNtsW_LfgXEsylt8qB_vbPZbZOixY-XULJptsxMfzu_2Z0ZhF7mmimwBBZKmZmQKKA7sCriMC4ibZRgWDUtWS4u0-GUnM3orJNxbbNLKnmofvw2r-R_tAr3QK82S_YfNLt5KdyAz6BfuIKG4frXOh5-t_W-FzaReADAVX5zFWMHo9HIsv2VKIw7dOEGv9h8EJ91tbWj2_FMbXuVpS_MtMmcdF_sxuDHpUWARkft-eBJvfxqritRN_s8H9og7NU14GqDvG20dVhLKdzZ-jMfltU-Iy_ymXgdUM3jMGWu8ugaVH19a2c8dLA4ZIyGzDVt8ljJXMsUv-z6sV8Q3QUXPm0mAb87oq9wDisrcAPSLmPrrfvLK346HY_55GQ2uYn2MNAH3EN7x-cfP5-35ZiTzBEj_9Y2t-uonep1RN_4abZclTsLsQLBF67zyW5q0rgok3vortdgcOwM5T66YeYP0K0Lf3riIXoH9hJ07CVoTCJo7CUAe3kbOGsJysIPbVnLIzQ9PZm8H4a-f0ZocJpXoTZJKiVAuslymgihtFbYGCnSXOYFIbiICkFFzMB70XlOYq3AuWM2NG6oBh6wj3rzcm4eo0AmBfD2ArxLRYlMqCAGkF5nWCW2X0DaR9laPty7bs4l46BH3p4kBNFyK1oeUd6IlpM-OtiSJ1-4Misc1gagDxj30Yu1gDlgn93QEnNT1ise04zZH7_7CeDz4JBm6e4ngDBlOciij_ad7jbz2073GcFP_vjyp-h2-794hnrVsjbPwVWt5IG3u5_XLZAI
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Hymenoptera+venom+study+III%3A+safety+of+venom+immunotherapy&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Lockey%2C+R+F&rft.au=Turkeltaub%2C+P+C&rft.au=Olive%2C+E+S&rft.au=Hubbard%2C+J+M&rft.date=1990-11-01&rft.issn=0091-6749&rft.volume=86&rft.issue=5+p.775-780&rft.spage=775&rft.epage=780&rft_id=info:doi/10.1016%2FS0091-6749%2805%2980182-4&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon